Biotech Values

[DaveAu]

Really nice to see the phase 3 results look even better than the much smaller Belmont study (at least on slide 13). Most phase 3 results seem to underperform versus phase 2. The stock price is still under where it peaked following Belmont. I would have expected a slightly bigger jump on this solid result today.